|
Study of Mast Cell Precursors Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Study of Mast Cell Precursors conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Study of Mast Cell Precursors Clinical research trials and Study of Mast Cell Precursors health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Study of Mast Cell Precursors. Study of Mast Cell Precursors Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Study of Mast Cell Precursors clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Study of Mast Cell Precursors condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Mast Cell Precursors  Study of Mast Cell Precursors
Study of Mast Cell Precursors
For Condition: Mastocytosis
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: This study will investigate mast cell precursors that circulate in the blood. In a group of diseases collectively known as mastocytosis, mast cells accumulate in abnormal amounts in the skin, lymphoid tissues, bone marrow, liver and spleen. Some forms of mastocytosis have a generally good prognosis; for others, the prognosis is poorer. There is no known cure for any form of the disease. A better understanding of mast cells and how they respond to certain substances may provide insights that will lead to effective treatments for mastocytosis. Patients with systemic mastocytosis and normal healthy volunteers between the ages of 20 and 60 may be eligible for this 8-day study. Participants will undergo the following procedures: - Day 1 - Medical history, physical examination, and blood tests to assess general health status - Days 2 through 6 - Daily injections under the skin of G-CSF-a hormone that stimulates white blood cell production - Day 7 - Leukapheresis-a procedure for collecting large numbers of white blood cells. In leukapheresis, blood is drawn through a needle placed in an arm and channeled into a cell separator machine. The white cells are collected and the rest of the blood is returned to the body through a needle in the other arm. The procedure takes up to 3 hours. - Days 7 and 8 - Blood draw (about 1 teaspoon) to monitor white blood cell counts.
Details: The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of patients with systemic mastocytosis and normal volunteers by leukapheresis for culture and characterization of mast cell progenitor cells and their response to various cytokines and anti-mitotic agents. Granulocyte colony stimulating factor (G-CSF) will be administered at doses of 10 micro g/kg/day as a single subcutaneous dose daily for 5 days. Normal volunteers and mastocytosis patients will be adults of both sexes from 18 to 60 years of age. Normal volunteers and patients will undergo a single leukapheresis at day 7. A small number of normal volunteers may undergo leukapheresis without G-CSF mobilization. This is not a therapeutic protocol and does not involve reinfusion of any manipulated cells, viruses or DNA constructs back into human subjects.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Normal Volunteers - ages 18-60: Healthy without active infection or history of recurrent infections. Normal renal function (creatinine less than or equal to 1.5 mg/dl; less than or equal to 1+ proteinuria); normal hepatic function (bilirubin less than or equal to 1.5 mg/dl); normal hematologic function (WBC greater than or equal to 3000/mm(3); granulocytes greater than or equal to 1500/mm(3); platelets greater than or equal to 175,000; hemoglobin greater than or equal to 12.5). Normal female volunteers of childbearing potential may be entered if using effective contraception, and with a negative urine pregnancy test determined the day before beginning G-CSF administration. Patients - ages 18-60: Systemic mastocytosis patients must have mast cell hyperplasia compatible with a diagnosis of systemic mastocytosis; and be without active infection or history of recurrent infections. Preserved renal function (creatinine less than or equal to 2mg/dl; less than or equal to 2+ proteinuria); preserved hepatic function (bilirubin less than or equal to 1.5 mg/dl); preserved hematologic function (WBC greater than or equal to 3000/mm(3), granulocytes greater than or equal to 1500/mm(3); platelets greater than or equal to 175,000; hemoglobin greater than or equal to 12.5). Normal female volunteers of childbearing potential may be entered if using effective contraception, and with a negative urine pregnancy test determined the day before beginning G-CSF administration. EXCLUSION CRITERIA: Normal Volunteers: Active bacterial, fungal or viral infections. HIV+ testing. Pregnancy or lactation. History of autoimmune disease such as rheumatoid arthritis, vasculitis, pyoderma gangrenosum or similar disorder. Use of any investigative drugs. Systemic Mastocytosis Patients: Active bacterial, fungal or viral infections. HIV+ testing. Patients taking any other growth factors, cytokines or investigative drugs. Patients hemodynamically unstable (blood pressure systolic of lower than 105 or diastolic lower than 65). Pregnancy or lactation. History of autoimmune disease such as rheumatoid arthritis, vasculitis, pyoderma gangrenosum or similar disorder. History of splenic rupture.
Total Enrollment: 100
Location and Contact Information:
National Institute of Allergy and Infectious Diseases (NIAID) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 980027; 98-I-0027
Study Start Date: November 5, 1997
Record last reviewed: September 11, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001756
Other Mastocytosis Studies:
1. Therapy of Hypereosinophilic Syndrome, Polycythemia Vera, Atypical CML or CMML with PDGF-R Fusion Genes, or Mastocytosis with Gleevec
2. Characteristics of Mast Cells in Mastocytosis
3. Stem Cell Transplantation to Treat Systemic Mastocytosis
4. Study of Mast Cell Precursors
5. Study of Factors Regulating Mast Cell Proliferation
Related Studies:
Other Mastocytosis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Study of Mast Cell Precursors
|
|
|
|
|
|
|
|
